Ajanta Pharma Paithan Facility Receives VAI Classification from USFDA

Ajanta Pharma Ltd has announced that its manufacturing facility located in Paithan, Maharashtra, has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA). The inspection, which took place from April 13 to April 21, 2026, has been classified as Voluntary Action Indicated (VAI). This classification suggests that while the inspection identified some issues, they are not considered significant enough to warrant mandatory regulatory action at this stage. The company had previously informed the stock exchanges about the inspection on April 22, 2026. This development is positive for the company's compliance status with USFDA standards.